Chronic inflammatory demyelinating polyneuropathy (CIDP) is the most common chronic immune-mediated neuropathy. It affects peripheral nerves and roots. CIDP has no biomarkers. It may be monophasic or ...
Vyvgart Hytrulo (efgartigimod alfa/hyaluronidase-qvfc) is a prescription medicine that is used to treat certain muscle and nerve conditions. It is a combination of two medicines, efgartigimod alfa and ...
The FDA expanded the indication of efgartigimod alfa and hyaluronidase-qvfc (Vyvgart Hytrulo) Friday to include treatment of adults with chronic inflammatory demyelinating polyneuropathy (CIDP), ...
Chronic inflammatory demyelinating polyneuropathy (CIDP) affects the peripheral nerves. Tests to diagnose this condition include nerve conduction studies, electromyography, and sometimes an MRI. CIDP ...
The traditional understanding of inflammation attributes the process primarily to immune cells responding to tissue damage or pathogen invasion. However, a growing body of research has revealed a ...
VYVGART ® is first-and-only targeted IgG Fc-antibody fragment for CIDP First novel mechanism of action for CIDP treatment in more than 30 years CHMP positive opinion based on ADHERE data, the largest ...
Inhibiting an immune signaling protein called TLR7 may help preserve the protective layer surrounding nerve fibers in the brain during both Alzheimer's disease and ordinary aging, suggests a study led ...
Physicians have long observed a mystifying phenomenon: After a bout of infection or an autoimmune disease flare-up, some people experience prolonged mood swings, emotional dysregulation, and changes ...
In recent years, there's been a growing awareness of neuroinflammation, an immune response in the brain. Research suggests that chronic inflammatory activation could be a central driver behind many ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback